Clear All
720 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9415 Doxorubicin Adriamycin 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1989 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9002 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jan 1, 2013 Dec 31, 2013 No Longer Used
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct 1, 2017 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
J9255 Methotrexate (Accord) Methotrexate 50mg Chemotherapy Antimetabolite Folic Acid Analog No 2014 Dec 7, 2023 In Use
C9095 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Mar 25, 2022 Sep 27, 2022 No Longer Used
J9057 Copanlisib Aliqopa 1mg Chemotherapy Enzyme Inhibitor PI3K No 2017 In Use
NA Diethylstilbestrol DES, Stilbestrol unspecified Hormonal Therapy Estrogen No 1905 2000 In Use
J3590 Immunotherapy - non specific Unclassified biologics NA Immunotherapy No Jan 1, 2003 In Use
J9176 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jan 1, 2017 In Use
C9477 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jul 1, 2016 Dec 31, 2016 No Longer Used
C9165 Elranatamab-bcmm Elrexfio 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Dec 7, 2023 Apr 17, 2024 No Longer Used
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
Q5130 Pegfilgrastim-pbbk Fylnetra 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
J9196 Gemcitabine HCl (ACCORD) Gemcitabine 200MG Chemotherapy Antimetabolite Pyrimidine Analog No 2011 Mar 17, 2023 In Use
J9203 Gemtuzumab ozogamicin Mylotarg 0.1 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2018 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 Jul 1, 2020 In Use
J9180 Epirubicin Epirubicin 50 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1999 Jan 1, 2001 Dec 31, 2003 No Longer Used
J0885 Epoetin Alfa Epogen, Procrit 1000 units Ancillary Therapy Erythropoiesis-Stimulating Agent No 1989 Jan 1, 2006 In Use
J9300 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2002 In Use
C9280 Eribulin mesylate Halaven 1 mg Chemotherapy Antimitotic Agent Furopyrans No 2010 Apr 1, 2011 Dec 31, 2011 No Longer Used
C9296 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan 1, 2013 Dec 31, 2013 No Longer Used
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan 1, 2019 In Use
C9147 Tremelimumab-actl Imjudo 1mg Immunotherapy Monoclonal Antibody CTLA-4 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
J1380 Estradiol Valerate Delestrogen 10 mg Hormonal Therapy Estrogen No 1954 Jan 1, 1997 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.